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ABSTRACT 
Use of tobacco has remained one of the most lethal pastimes within the United States. With the 
creation of new products, like electronic cigarettes (e-cigarettes), more and more individuals 
have begun to engage in this activity. In 2019, an epidemic surrounding the use of e-cigarettes 
emerged causing a multitude of users to suffer harmful respiratory illnesses. These events 
triggered the need for further investigation not only into the research used to analyze e-cigarettes, 
but also the regulation process used to validate them.  E-cigarettes, like their predecessor 
traditional cigarettes, are regulated by the Center for Tobacco Products (CTP) within the United 
States Food and Drug Administration (FDA). Through premarket tobacco product applications 
(PMTA), the CTP determines whether tobacco products are safe for public use. This thesis was 
used to investigate whether the current regulatory process is able to effectively analyze all of the 
risks and health implications associated with the use of e-cigarettes. After reviewing research 
from literature to define the current state of knowledge surrounding the health impacts of e-
cigarettes, an applied case study was conducted to determine whether the research in the PMTA 
was sufficient in assessing the safety of these devices. The findings of this research reveal that 
although the PMTA included some of the important research areas found in the literature review, 
its analysis was limited due to the continuous reliance on the comparison of e-cigarettes and 
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CHAPTER 1: INTRODUCTION 
Within the United States, the use of tobacco remains one of the most hazardous 
recreational activities, resulting in over 480,000 preventable deaths per year (Centers for Disease 
Control and Prevention [CDC], n.d.a). Since their creation in the 19th century, traditional 
cigarettes have steadily increased in popularity throughout society (“History of Tobacco”, n.d.). 
Although they remain popular, traditional cigarettes are only one type of tobacco product. Other 
tobacco products on the market include: cigars, snuff, chewing tobacco, hookah, and most 
recently electronic cigarettes (e-cigarettes). The creation of these devices classified as e-
cigarettes or electronic nicotine delivery system (ENDS) has introduced a rapidly expanding 
market, especially in the United States. The users of e-cigarette devices are comprised of not 
only adults, but also children. In 2018, the United States Food and Drug Administration (FDA) 
noted that 3.62 million middle and high school students are e-cigarettes users and in 2019, this 
same number escalated to 5 million.  (U.S. Food and Drug Administration [FDA], n.d.e, n.d.d). 
Although e-cigarettes have been approved by the Center for Tobacco Products (CTP) 
within the U.S. Food and Drug Administration (FDA), emerging evidence has revealed that these 
devices are potentially more hazardous than previously publicized (Knowles and Sun, 2019). 
Little research has been done to accurately assess all of the health effects, both short- and long- 
term, of these devices (Sharpless, 2019.) Specifically, no research has been done to evaluate the 
potential negative health effects caused by the ingredients in e-cigarette liquids. For example, 
although deemed safe by the FDA, propylene glycol, a compound commonly used in e-cigarette 
liquids (e-liquids), was only researched for use in topical, oral, and injectable consumer products 
(Cobb and Abrams, 2011). Since the e-liquids change from liquid to vapor, inhaling propylene 
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glycol could stimulate alternative effects from those previously seen in the research of approved 
consumer products.  
There is a vast amount of variability amongst types of e-cigarettes. Currently, e-cigarettes 
are classified by their product design; some resemble USB flash drives, while others 
resemble pens. Diversity of design, however, is not the only variable factor within these devices. 
There are a multitude of ingredients that make up the e-liquids used in e-cigarettes. In 2014, 
there were not only 466 different brands of e-cigarettes, but also 7764 distinctive flavors being 
sold online (Zhu et al., 2014). The addition of flavors creates vast differences, particularly, in the 
concentration of nicotine being used in the formulas. Although the ability to modify and 
customize e-cigarettes is commonly used as a marketing ploy by companies to increase the sale 
of their products (Zhu et al., 2014), the diversity of e-cigarettes also warrants questions 
surrounding both the risks to e-cigarette users and the efficacy of the regulation process in 
analyzing these devices. These modifications could potentially impact both the function and the 
use of the device, which could alter how they should be analyzed. 
Recently, there has been an abundance of events surrounding the development of 
respiratory illnesses in e-cigarettes users. Many individuals have succumbed to acute respiratory 
distress syndrome, a life-threatening condition caused by the accumulation of fluid in the lungs, 
which obstructs the circulation of oxygen in the bloodstream (Knowles and Sun, 2019), 
preventing the 
body from functioning properly. The latest outbreak information indicates that there has been 
almost 1479 e-cigarette associated respiratory injury cases and 33 confirmed deaths (CDC, 
n.d.d).  
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 Due to the rising number of cases, state officials have taken legislation of e-cigarettes 
into their own hands, allowing them to decrease the regulatory void created by the indolence of 
the federal government (“Outbreak of Lung Injury”, n.d.). Michigan, for instance, was the first of 
many states to create e-cigarette legislation. The state government limited the sale of e-cigarettes 
by placing an emergency ban on all flavors other than tobacco. In February of 2020, the resident 
officially enacted a federal ban on the flavored e-cigarette products. 
 The overall goal of this thesis is to determine whether the regulatory process for e-
cigarettes allows for effective review of the safety of e-cigarettes. The thesis will focus on one of 
the only Premarket Tobacco Product Applications available to the public.  By evaluating the 
content in the PTMA, I will be able to examine what characteristics are included when assessing 
the harmfulness of e-cigarettes and determine whether the evaluation of these characteristics is 
sufficient by comparing them research found within the broader academic literature. I will also 
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CHAPTER 2: RESEARCH QUESTIONS 
There is a lot of variation between cigarettes not only in their design, but also in their 
auxiliary components, like e-liquids. Although substantial equivalence can be used to show that a 
device is similar to an already marketed device, how do we know whether the disparity between 
the devices does not have hazardous health consequences? Of the 302 applications submitted 
during the 2019 fiscal year, 296 applications were submitted through the substantial equivalence 
pathway (FDA, n.d.a).  If there is a comparison being made, between electronic cigarettes or 
even traditional cigarettes, then what are areas the of research being used to examine their 
similarities?  
The research of this thesis focuses on the regulation of e-cigarettes. In 2019, there was 
not only a large growth in the number of youth users, but also a large number of individuals who 
became impaired, even hospitalized, due to their use of these products. Through regulation, these 
devices were able to receive a marketing order, which means that they were proposed to be safe 
for the public. In order to create a solution, we have to determine where the problem occurs. 
Thus, the process of regulating these devices needs to be analyzed in order to determine what 
factors inhibited the regulation process from uncovering the health problems associated with the 
device.  The research within this thesis surrounds two large questions: 
- Is the evidence provided in PTMAs adequate to claim substantial equivalence?  
- Has the Premarket Tobacco Product Applications (PTMA) been effective in the 
regulation of e-cigarettes? 
 The first question looks at the information that companies provide within their PMTA. I 
will look at what scientific research companies supply for the Substantive Review phase of the 
PMTA process. This will allow me to examine the findings of their research, assess the quality of 
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research, and compare their findings with the literature. From this information, I cannot only 
determine what evidence is provided, but also whether it is substantial in the analysis of e-
cigarette devices. 
The second question surrounds the one of the main functions of the Family Smoking 
Prevention and Tobacco Control Act (FSPTCA), which is to create a process that effectively 
regulates e-cigarettes, a type of tobacco product. To determine the effectiveness of the process, 
we have to determine whether the research included in the PMTA incorporate all of the areas 
important in analyzing the devices. Important areas will be determined decided by the areas that 
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CHAPTER 3: BACKGROUND 
Beginning in the 1960s, there has been a multitude of policy measures that have impacted 
both the advertisement and use of tobacco products. From the Federal Cigarette Labeling and 
Advertising Act of 1965 to the Public Health Cigarette Smoking Act of 1969, tobacco products 
have been a controversial topic within legislature (Centers for Disease Control and Prevention, 
n.d.c). In 2009, President Barack Obama gave the FDA the ability to regulate tobacco products 
through the creation of the Family Smoking Prevention and Tobacco Control Act (FSPTCA) 
under the Food, Drug, and Cosmetic Act. In addition to producing standards for tobacco 
products, the FDA can require companies to disclose both the contents of their products and the 
research used to evaluate their health effects (Public Health Center, n.d.).  
Before being placed on the market, “new tobacco products” have to receive a tobacco 
product marketing order from the FDA. “New tobacco products” are defined as tobacco products 
that were not commercially marketed before February 15, 2007. In order to receive approval, 
companies can go through three different pathways: submitting of a premarket tobacco product 
applications (PMTA), demonstrating substantial equivalence, or requesting an exemption from 
substantial equivalence. These applications allow the FDA to assess the benefits and risks of the 
product on public, both users and non-users (FDA, n.d.c). Therefore, all tobacco products, 
including e-cigarettes must go through this regulatory process, as shown in Figure 1.   
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The process begins with a Presubmission Meeting, an optional meeting between the 
company and the Center for Tobacco Products (CTP) where the company can receive guidance 
and assistance regarding their plans prior to submitting the PMTA. After the submission of the 
PMTA, the CTP conducts an Acceptance Review to confirm whether the product falls under its 
jurisdiction. Following the Acceptance Review, the Filing Review phase is used to verify that the 
PMTA includes all the necessary items. This thesis is focused on the step that succeeds the Filing 
Review, the Substantive Review. Substantive Review determines whether companies will 
receive a marketing order letter for their device which is officially granted in the Action phase of 
the process. Substantive Review is the phase where the CTP examines the scientific research that 
was submitted within the PMTA and provides recommendations. Within this step, the scientific 
research is used to provide evidence showing the health-related effects related to the tobacco 
product, allowing the CTP to assess its safety. Postmarket Reporting is the last phase of the 
process. After receiving a marketing letter, the FDA requires companies to keep information on 
the product. 
E-cigarettes are battery operated devices classified by their ability to heat liquids into 
aerosols, a mixture of liquid or solid particles in a gas. Initially, in 2011, the FDA wanted to 
regulate electronic cigarettes as drug delivery devices. However, since there were no therapeutic 
claims surrounding the devices, the courts denied their request and required e-cigarettes to be 
regulated as tobacco products citing the FSPTCA as the reason for the ruling (Cobb and Abrams, 
2011). The first e-cigarette was created in the 1960s, when Hebert A. Gilbert submitted a patent 
for a ‘smokeless nontobacco cigarette’, an alternative to smoking cigarettes (U.S. Department of 
Health and Human Services et al., 2016, p.10). E-cigarettes have four common pieces within 
their design: a power source, a heating element, a pressure switch, and a battery. First generation 
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e-cigarettes are classified by their likeness to traditional cigarettes. These devices resemble both 
the look and the feel of traditional cigarettes, becoming an alternative for smoking. Second 
generation e-cigarettes are devices characterized by two elements, an atomizer or thin battery, 
and a clearomizer, a clear cartridge that holds the e-liquids (“E-cigarette Devices, Uses”, 2018). 
Unlike the first two generations, third generation e-cigarettes bear no resemblance to traditional 
cigarettes. They are classified by the ability of their parts to be customizable, replaceable, and 
refillable. 
 
Figure 2: The image above illustrates the differences between the various generation of e-
cigarettes (Truth Initiative, 2019). 
The main difference between e-cigarettes and traditional cigarettes is the absence of 
tobacco in e-liquids. Unlike traditional cigarettes, e-cigarettes contain nicotine, an addictive 
substance found in tobacco. Products like e-cigarettes and other non-smokable products are 
perceived to be less harmful by the public not only because they have lower concentrations of 
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harmful chemicals, but also because they do not rely on combustion (Pepper et al., 2014). 
Although the ingredients within the e-liquid, for instance nicotine, are less concentrated, they 
still have deleterious effects. Diseases associated with smoking traditional cigarettes, like lung 
cancer and emphysema, develop after years of constant smoking. Recent events, however, have 
shown that damage to the lungs can occur in less than a year (“Is Vaping Safer than”, 2019). 
Table 1 lists some of the ingredients mentioned by the American Lung Association that are 
typically found in e-cigarettes. 
 
Table 1: List of Ingredients in e-cigarettes compiled from American Lung Association. 
Ingredients Uses 
Propylene glycol Common food additive. Used to make 
antifreeze and paint solvent. 
Acrolein Herbicide used to kill weeds 
Diacetyl Chemical linked to bronchiolitis obliterans 
(popcorn lung) 
Benzene Volatile compound found in car exhaust 
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CHAPTER 4: METHODS 
The methods of the thesis can be separated into two parts, the methods for the literature 
review and the methods used to find the premarket tobacco product applications (PMTA). 
 
Literature Review 
The information gathered within this literature review is separated into three different 
categories: various generations of e-cigarettes, the comparison of e-cigarettes to traditional 
cigarettes, and the comparison of the materials in both e-liquids and aerosols. To find materials, 
two different databases, google scholar and RIT library were utilized. The search terms include: 
“health e-cigarettes”, “chemicals in e-cigarettes”, “chemical in e-cigarettes”, “e-cigarette 
flavor compounds”, “first generation e-cigarettes”, “second generation e-cigarettes”, “third 
generation e-cigarettes” and “traditional and e-cigarettes”. Through the multiple searches, 
seventy papers were found. 
Since the material within this literature review was being used to identify important 
research, it was imperative that they were experimental research that looked at the health effects 
associated with e-cigarettes. Many of the documents that came back were patents of e-cigarettes 
and news articles of current events. Patents were excluded from this review because although 
they illustrate the versatility in design, patents are unable to show whether the design of e-
cigarettes impacts the health of its users. News articles provide good background information, 
but they do not provide data in relation to the scientific analysis of e-cigarettes. They can account 
for what injuries are frequent amongst users, but they cannot show the relationship between what 
is causing these health-related issues; thus, they were also excluded from this literature review. 
Other research that was excluded includes research that focused only on defining the differences 
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without discussing the impact on health. The absence of health impact would not allow this paper 
to gather enough information about the implications that versatility could potentially have on 
health. After refining the search criteria, twenty-seven papers were selected to provide data that 
would allow me to find ideas that were prevalent amongst different areas of research. 
 
Applied Case Study 
Locating the premarket tobacco product applications was a difficult task. The Food and 
Drug Administration, which is made up of several centers, had a lot of information that on its 
website. I had to use the FDA search for the information that I was hoping to acquire. After 
locating the applications with the ‘premarket tobacco application’ search term, I was able to 
examine applications using the seventh link titled, “Premarket Tobacco Product Marketing 
Order” (FDA, n.d.b). The page listed marketing orders for PMTAs from two separate years, 
2015 or 2019. Within these two years, there was a total of four PMTAs e-cigarette devices, 
however, they were all under the 2019 fiscal year and submitted by one company, Phillip Morris 
S.A. (FDA, n.d.b).  
Since the analysis of this thesis relied heavily on the details of the PMTA, the acquisition 
of these documents was a sizable limitation. I did not want to rely solely on a few PMTAs, 
especially since they were all submitted by a single company. In order to rectify the situation, I 
attempted to obtain more applications. Initially, I reached out to several individuals and 
departments associated with the FDA through email and phone to initiate correspondence about 
finding additional PMTAs, however, I was not able to find more information through this route. 
The information provided by these sources referred me back to information I already acquired 
when searching the FDA website. In addition to this, through the help of my advisor, I was able 
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to use a resource called MuckRock. Through the Freedom of Information Act, MuckRock is able 
to assist individuals in gathering government documents. Through this platform, I requested to 
see e-cigarette PMTAs from 2018, however this request was denied. In March, I received a 
response, located in appendix 1, which noted that the existence of PMTAs could neither 
confirmed nor denied, referencing “Extemption 4 of the FOIA and 21 CFR 20.61 (b)(c)” 
(appendix 1). 
 Since I was unable to acquire additional PMTAs, I was restricted to the four applications 
submitted by Phillip Morris S.A that I located on the FDA website. These four applications were 
based on the flavor of the heatsticks (3) that were used in the devices and the actual system. 
Under closer examination, I found that there were no major differences between them and that 
they all included similar information and research. Thus, I chose to focus on one of the 
applications for this thesis. The specific application analyzed was the first of the four 
applications located on the ‘Premarket Tobacco Product Marketing Order’ page under the 
PMTAs for the 2019 fiscal year, titled ‘PM0000424’, associated with the Marlboro Menthol 
Heatsticks. 
The PMTA was organized in five different sections: Executive Summary, Review of 
PMTA, Product Labeling, Consumer Comprehension, & Marketing Plan, and Conclusions & 
Recommendations (FDA, 2019, p. 6-7). The second section, Review of PMTA, contained three 
subsections that focused on the experimental research done to analyze the device. The three sub-
sections were: Toxicological Risk Assessment, Behavioral & Clinical Pharmacological 
Assessment, and Individual Health Impact. Although these sections contained information about 
the experiments, they mostly were a summary of the experiments and commentary from 
 Lara 14 
individuals from the CTP. For example, most of the quantitive data was excluded from the 
PMTA. 
To develop a clearer understanding of the evidence, I attempted to find the 
documentation of the actual experiments. Three experiments were found by using the 
experimental numbers that were referenced within the PMTA. The first experiment, which 
focused on smoking topography was referenced as ‘ZRHM-REXA-08’. The next experiment, 
referenced by ‘ZRHM-PK-06-US’, was focused on pharmacokinetics. The final experiment 
number, ‘RLS-ZRH-2015-249, included details about all of the in vivo experiments that focused 
on aerosol toxicity.  
To find the detailed information about the experiments executed in the PMTA, a google 
search was conducted using the experimental number with the addition of the search term 
‘pmiscience’. For example, for the data for the smoking topography was found using the search 
term ‘ZRHM-REXA-08 pmiscience’. There were some redactions within PMI science documents, 
however, they did not take away from the data or the findings of the experiments.  
  
Analysis 
Gathering and organizing the scientific research collected was an immense portion of this 
thesis. The first analysis was conducted during the literature review, resulting in the definition of 
the important research areas for e-cigarettes. These areas helped to organize the research of the 
PMTA into three sections: Smoking Topography, the Pharmacological Assessment of Nicotine, 
and Aerosol Toxicity. From the experimental research of the experiments within the PMTA, 
each experiment was detailed to develop of an understanding of what was done and to learn the 
findings. In addition to defining the research areas, the research from the literature review was 
used for a comparison. The findings from those papers were compared to the experiments 
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conducted within the PMTA. In addition to the comparison between the research, the findings 
were organized by their potential for health impact by denoting them as ‘low’, ‘medium’, and 
‘high’. This was used to help categorize the information establishing a correlation with 
importance. High health impact implies that it there is a high importance when assessing the 
health effects during the analysis of these devices. The results of the research comparisons thesis 
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CHAPTER 5: FINDINGS 
Findings can be broken in three sections: research areas within literature important in 
evaluating e-cigarettes, experimental areas included within the premarket tobacco product 
application (PMTA), and the assessment of research quality within the Pre-market tobacco 
application. In addition to showing the importance of different e-cigarette areas that are 
researched, I will also make several comparisons between what is shown in literature, what is 
provided in the PMTA, ultimately, determining whether the evidence provided in the PMTA is 
substantial enough to be considered safe for consumers. 
I will review my findings, starting with a review of areas and ideas that are critical when 
analyzing the health effects of e-cigarettes. After defining these research areas, I will use them to 
organize the experiments of the PMTA and see what evidence, if any, was provided. Following 
the discussion surrounding the findings of each experiments, I will then compare the findings of 
research used in the literature review to the findings of the PMTA. Finally, I will assess the 









 Lara 17 
CHAPTER 5A: AREAS THAT IMPACT SMOKING (LITERATURE REVIEW) 
Within the literature, research areas are able to provide evidence about what should be 
considered when evaluating electronic cigarettes. In order to be considered safe and receive a 
marketing order, tobacco products, like e-cigarettes, have to be tested to show the effects 
associated with their usage. Both harmless and hazardous effects should be considered because 
they play a role in the assessment of risks that consumers could potentially encounter. When 
there is consistency between findings of research, it allows the importance of that subject area to 
be emphasized. For instance, if the majority of research made claims that smoking behavior is 
different in e-cigarettes, then the research within the PMTA should include research that 
examines smoking behavior.   
Findings do not always agree between research. This does not mean, however, that these 
research areas are insignificant. Contrasts between findings in research show not only 
inconsistencies between research, but also the need for further research in these areas. These 
areas are also important in showing the risks of these e-cigarettes. Including these research areas 
would be valuable addition to the regulatory process so that it could ensure that its review of 
these devices is truly comprehensive. 
  Within the three categories below, a variety of research was used to examine the different 
ideas and whether they were consistent. The three main focuses of the papers are the comparison 
of the various generations of e-cigarettes, the comparison of e-cigarettes to traditional cigarettes, 
and the comparison of the materials in both e-liquids and aerosols. These comparisons help to 
identify areas that are necessary in assessing the harmfulness of the e-cigarettes. 
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Electronic versus Traditional Cigarettes 
Electronic and traditional cigarettes differ, especially in their usage. Eight papers were 
used to develop the comparisons of this section. The papers within this section are limited. Four 
of the papers only look at the short-term effects cause by the usage of e-cigarettes. Although the 
other papers were not classified as having a short-term evaluation of health effects, their time 
periods of evaluation were still short in comparison to the period it takes for noticing a different 
in health effects. The longest evaluation time within this section which occurred in the study 
conducted by Harrington, Cheong, Hendricks, and Kohler (2015) was 6 months. The most 
common idea throughout these papers was a difference between the usage of e-cigarettes 
compared to traditional cigarettes. In one study, researchers found that the participants 
significantly increase the average time they puffed on e-cigarettes (Ceriana et al., 2015). Another 
study also showed that although e-cigarettes deliver less nicotine to their users, the devices were 
smoked more intensely than traditional cigarettes (Norton et al., 2014). After finishing, these 
participants were also less satisfied.  
 
Table 2: Ideas in Literature about Electronic and Traditional Cigarettes 
 Short Term 
Evaluation of 




Difference between the 
usage of e-cigarettes and 
traditional Cigarettes 
(Pepper et al., 2014)    
(Ferrari et al., 2015) X   
(Vargas Trassierra et al., 2014) X X X 
(Papoušek et al., 2014) X  X 
(Lee et al., 2015)  X X 
(Harrington et al., 2015).  X X 
 Lara 19 
(Farsalinos et al.,  2017)  X X 
(Norton et al. , 2014) X X X 
Generations of E-Cigarettes 
The papers within this section have two major ideas. E-cigarette users have preference 
over the design of the e-cigarettes. E-cigarettes also have a difference in the delivery of nicotine, 
which is dependent on the design. Research conducted in one of the papers found that third 
generation e-cigarette users consume twice the amount of e-liquid compared to second 
generation e-cigarette devices (Dawkins et al., 2014). 
 
Table 3: Ideas in Literature in relation to Generation of E-cigarettes 












(Rüther, et al., 2017) X X X X 
(Dawkins et al., 2014) X X X X 
(Chen, Zhuang, & Zhu, 2016) X   X 
(Lechner et al., 2015) X  X  
(Wagener et al., 2016) X  X  
(Farsalinos et al., 2015). X X X  
 
E-liquids and Aerosols 
The research in this category differed by the variables researchers chose to measure. 
Some looked at the particles in the aerosol, while others looked at the chemicals in the user’s 
body. Two major findings within this section were that e-liquids alter the behavior of the smoker 
and that the design of the device impacts the aerosols. For the first finding, seven papers 
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illustrated how the behavior of the smoker was altered by the e-liquid. For example, in one study, 
higher levels of carbonyls were related to intensive puffing. This demonstrated that individuals 
using e-liquids of lower nicotine concentration puff longer to increase their exposure of these 
nicotine (Corcoran et al., 2017). The second finding illustrated how design of the e-cigarettes 
impacts the aerosol of e-cigarettes. In a study, researchers found higher concentrations of metals 
in the e-liquid within different areas of the e-cigarette devices (Olmedo et al., 2018). The tank 
and the aerosol had the highest level of metal concentrations, indicating that e-liquid 
contamination is occurring throughout the process of using e-cigarettes. 
 
Table 4: Ideas in Literature about E-liquids and Aerosols 
 E-liquids 
can alter the 
behavior of 
the smoker  
The level of substances 
(metal, compounds, 










impact the aerosol 
of the e-cigarettes 
(Corcoran et al., 2017) X    
(Pourchez et al., 2018) X X   
(St. Helen, 2018)   X  
(Strongin, 2019) X   X 
(Kaur et al., 2018) X   X 
(Erythropel et al., 2018) X   X 
(Korzun et al., 2018)  X X  
(Klager et al. 2017)    X 
(Dawkins et al., 2016)  X  X 
(Dawkins & Corcoran, 
2013) 
X    
(Papoušek, 2014)    X 
(St. Helen, 2017) X    
(Olmedo et al., 2018)  X  X 
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Overall  
The papers gathered for this literature review provide insight into how the different 
components of e-cigarettes affect their usage. Compared to traditional cigarettes, e-cigarettes are 
used differently, which can be illustrated through the differences in the smoking behavior of the 
users. Also, the creation of e-cigarettes, initially, was to provide aid in smoking cessation, 
however, there are contradictions in the findings provided by the literature. When comparing 
traditional cigarettes to e-cigarettes, Harrington et al. (2015) found that while e-cigarettes 
decrease the frequency of smoking, they are not effective in promoting smoking cessation. This 
finding differs from the research of Chen et al. (2016) where they found that second generation 
devices promote both smoking cessation and satisfaction.  
 E-cigarettes also differ from traditional cigarettes due to their ingredients. Although there 
are lower concentrations of harmful ingredients within e-cigarettes, it should not discount the 
fact that they are still harmful. Allen et al. (2017) found that all of the e-cigarettes contained 
chemicals that were considered dangerous by the FDA or Federal Emergency Management 
Agency (FEMA). Most of the research conducted illustrate that traditional cigarettes have higher 
toxic ingredients; however, this should not be the only benchmark to assess the healthiness of e-
cigarettes. The comparison only shows that e-cigarettes are better than traditional cigarettes, not 
that they are harmless. Also, other considerations have to be made when assessing the harm of e-
cigarettes. There is an abundance of chemical reactions undergone throughout the vaping 
process. For example, Erythopel et al. (2018) found that the conversion of aldehydes, a highly 
reactive functional group, to acetals initiate the activation of irritant receptors within cells. 
Therefore, the contents of the aerosols become an important indicator of exposure to harmful 
materials.  
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Most of the papers, regardless of the subject area, focused on the topography, or smoking 
behavior of the users. Research by Dawkins et al. (2017) and Lee, Gawron, and Goniewicz 
(2015) have different objectives, however, they were both conducted similarly utilizing patient 
studies to collect user data. From the data, they were able to compile measurements regarding the 
number of puffs, the duration of the puff, and the satisfaction of the user. Another common 
finding between the research is the measurement of nicotine levels, which could be collected 
from either the blood stream or aerosol of the users. Corcoran et al. (2016) measure nicotine 
levels within the bloodstream while Farsalinos et al. (2017) measure nicotine levels within 
aerosols. The final idea prevalent in the research is the ingredients within these e-cigarettes, 
which can be examined through the e-liquids or the aerosols created by the device. From this 
information, several areas appear significant when evaluating e-cigarettes: Smoking Topography 
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CHAPTER 5B: CONTENTS OF PMTA 
The Premarket Tobacco Product Application (PMTA) is broken into five distinct 
sections: Executive Summary, Review of the PMTA, Product Labeling, Consumer 
Comprehension, & Marketing Plan, and Conclusions & Recommendations. Specifically, Review 
of the PMTA contains multiple subsections selected by the Center for Tobacco Products as areas 
necessary for the evaluation of the electronic cigarette device created by the Phillip Morris S.A. 
These research areas include but are not limited to behavior clinical pharmacology, chemistry, 
environmental science, epidemiology, and toxicology. This section is used to examine the 
research Phillip Morris included in the PMTA. Particularly, experiments categorized under that 
areas from literature review that were deemed important.  
 
Smoking Topography 
Smoking topography describes the behavioral patterns of a smoker. It encompasses 
elements such as the number and length of individual puffs a person takes while smoking 
(Robinson et al., 2018).  Through behavioral analyses, topography can illustrate the difference in 
smoking regimens between different types of smokers and even the selection of settings on a 
smoking machine used by researchers to replicate human smoking behavior.  
Within the PMTA, Phillip Morris S.A. conducted four studies looking at the behavior of 
individuals in the United States(1), Europe(1), and Japan(2). Within the United States, the study 
observed 160 participants over a 91-day period, including 5 days within a confined setting and 
86 days within an ambulatory setting. Participants consisted of healthy individuals who were at 
least 22 years and older and smoked at least 10 menthol cigarettes per day (Lewis and Farmer 
2016).  There were three different groups within the study: 
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- Experimental group: Individuals who used the THS 2.2 Menthol device ad libitum for 
5 days in the confined environment and 86 days in an ambulatory environment 
-  Active comparator group: Individuals who used their own preferred brand of 
traditional menthol cigarettes ad libitum for 5 days in the confined environment and 
for 86 days in their ambulatory environment. 
- Sham Comparator group: Individuals who abstained from smoking for 5 days in a 
confinement environment and 86 days in an ambulatory environment 
 
For evaluation of the Phillip Morris S.A product, participants were given a self-report 
questionnaire called the Modified Cigarette Evaluation Questionnaire. From this survey, 
researchers were able to compare the craving reduction, enjoyment of respiratory tract sensation, 
and smoking satisfaction between the experimental group and the active comparator group. 
Researchers found that every category was lower for the experimental group, the individuals 
using the Phillip Morris S.A. device. Table 5 illustrates the statistical analysis of the results 
collected from the survey (Farmer and Lewis, 2016).  
The researchers noted that over time these variations between the groups decreased, so 
there were no notable differences. However, these decreases in magnitude over time can be 
explained not only by the differences in smoking topography between the smokers, but also due 
to the active comparator group using their preferred cigarettes, resulting in stability of their data. 
Upon closer examination, although craving reduction was lower, the category was still higher in 
magnitude compared to any of the other categories. If cravings are not reduced by the device, 
then it introduces the questions of whether individuals are actually satisfied and whether they 
would smoke more due to the lack of reduction in their urge to smoke.  
 Lara 25 
Table 5: Results from the Modified Cigarette Evaluation Questionnaire during the 91-day US 
study comparing users smoking traditional menthol cigarettes or the Phillip Morris S.A. device, 
THS 2.2 Menthol (Lewis and Farmer, 2016). 
 
Within the clinical study, smoking topography was characterized by examining puff 
volume, puff duration, flow, and puff frequency. During the ambulatory phase, researchers 
observed differences in average flow, total number of puffs, puff frequency, and total smoking 
time between the two groups. Although users of the THS 2.2 Menthol device had a shorter 
smoking time, they had higher total numbers of puff, puff frequency, and average flow. The 
value of these differences can be found below in Table 6. 
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Table 6: Smoking Topography comparisons in the ambulatory phase of the study (86 days) 
comparing smokers using traditional cigarettes of the Phillip Morris S.A device. 
Category Difference 
 
Larger for Individuals using the 
THS 2.2. Menthol Device 
Average Flow (mL/s) 7.41 x 
Number of Puffs 3.34 x 
Smoking Duration (min) 1.5  
Puff Frequency (puff/min) 2.22 x 
 
Pharmacological Assessment of Nicotine 
Pharmacology describes the interactions of drugs within the body. It is commonly broken 
in to two areas of study: pharmacodynamics (PD) and pharmacokinetics (PK). 
Pharmacodynamics surrounds the response of the body due to the drug, while pharmacokinetics 
surrounds the movement of the drug itself (“Pharmacokinetic & Pharmacodynamic Services: 
Nuventra.”, n.d.).  Nicotine is commonly found in tobacco products, including the THS 2.2 
Menthol device. Within the PMTA, Phillip Morris S.A. included data collected from a study 
used to research the PK and PD of nicotine from three different products, the heatstick of the 
THS 2.2 Menthol device, traditional menthol cigarettes, and nicotine nasal spray (NNS). The 6-
day study was comprised of healthy individuals between 22 and 65 years old who smoked for at 
least 3 consecutive years and smoked at least 10 traditional menthol cigarettes per day (Borders, 
n.d.). The study was broken into two periods which each consisted of one day (at least 24 hours) 
of nicotine abstinence and 1 day using one of the products.  During the study, the participants 
interacted with two of the three nicotine products. There were four groups, which differed by the 
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sequence of interaction the participants had with the products during the periods. They are as 
follows: 
- Group 1: single heatstick of the THS 2.2 Menthol (period 1) | ad libitum use of 
traditional menthol cigarette (period 2) 
- Group 2: ad libitum use of the traditional menthol cigarette (period 1) | single heatsick 
of the Nasal nicotine Spray (period 2) 
- Group 3: single heatstick of the THS 2.2 Menthol (period 1) | single heatstick of the 
one spray per nostril of the Nasal Nicotine Spray (period 2) 
- Group 4: one spray per nostril of the Nasal Nicotine Spray (period 1) | THS 2.2 
Menthol (period 2) 
 
Within the experiment, there were two pharmacokinetic comparisons, one between the 
THS 2.2 Menthol device & traditional menthol cigarette and another between the nasal nicotine 
spray & THS 2.2 Menthol device. The pharmacokinetic comparisons illustrate the relationship 
between the concentration of nicotine in the bloodstream (plasma) over time, ranging from 0 to 
24 hours. Between the traditional cigarette and the heatstick, the shapes of the PK nicotine 
concentration-time curves were similar however, there were lower concentrations of nicotine for 
smokers using the heatstick compared to the nicotine cigarettes. Another difference was the time 
necessary to reach the maximum nicotine concentration, which was shorter for the heatstick. The 
exposure of nicotine, denoted by the area under the nicotine pharmacokinetic curve to the last 
quantifiable concentration (AUC 0-last), was lower for the heat stick compared to the traditional 
menthol cigarette, 16.5 ng*h/mL and 29.7ng*h/mL, respectively. After completion of the 
statistical analyses for both products, researchers noticed large amounts of between-subject 
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variability, which indicates that the relationship of the nicotine within the plasma differed 
between individuals in the study. 
 Conversely, the next comparison, between the heatstick and the nicotine nasal spray, 
showed different results. Specifically, the exposure to nicotine, denoted by AUC 0-last, was 
significantly higher for e-cigarettes. The values were 15.6 ng*h/mL and 8.7 ng*h/mL, 
respectively. However, researchers still noticed very large values for the between-subject 
variability for all of the pharmacokinetic parameters that were analyzed. 
Due to its longevity within the body, cotinine, a metabolite of the nicotine, is commonly 
used as another method to analyze nicotine exposure (CDC, n.d.b).  Another portion of the study 
focused on the plasma cotinine levels, beginning after at least 24 hours of smoking abstinence 
and before using the nicotine product, which is indicated by To. There were three time points 
used in the analysis: To, To+12hr, and To+24hr. Between the two cigarettes, the traditional and 
the electronic cigarettes, the concentration of cotinine were similar between 12 hours, however, 
after the 24 hours the concentration decreased further than baseline. This ultimately was not was 
not significant. The values are indicated below in Table 7. 
 
Table 7: Average plasma cotinine concentrations used to evaluate nicotine exposure within 
individuals who smoked using either the THS 2.2 Menthol device or the traditional menthol 
cigarettes  
 THS 2.2 Menthol 
device (ng/mL) 
Traditional menthol cigarette 
(ng/mL) 
To   38.0 29.4 
To  + 12 hr 29.8 33.5 
To + 24 hr 20.8 25.7 
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The study also looked at the differences between the plasma cotinine concentrations for 
individuals using the NNS and the THS 2.2 Menthol device. The same time points were used as 
in the previous comparison between the THS 2.2 Menthol device and the traditional menthol 
cigarette. As shown in Table 8, there is decline within both of these products over time. There 
are differences between the values of the nicotine nasal spray and the Phillip Morris S.A. device, 
however, researchers classified these differences as insignificant. 
 
Table 8: Average plasma cotinine concentrations used to evaluate nicotine exposure within 
individuals who smoked using either the THS 2.2 Menthol device or the nicotine nasal spray 




To   28.2 27.3 
To  + 12 hr 24.3 21.2 
To + 24 hr 17.1 14.2 
 
Aerosol Toxicity 
 When looking at the toxic effects of the THS 2.2 Menthol device, Phillip Morris S.A. 
submitted data from both in vitro and in vivo clinical studies. Within the research, Phillip Morris 
S.A. focused on the comparison between the aerosols of the heat stick from THS 2.2 Menthol 
device and the smoke created from the 3R4F, a standard reference traditional cigarette created by 
the University of Kentucky College of Agriculture (“3R4F”, n.d.).    
 Before those studies, an initial test was completed to determine the different chemicals 
within the aerosols and smoke of the respective products. The screening of the two tobacco 
products indicated that there were 80 chemicals in the heatstick aerosol that were in higher 
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concentration or non-existent compared to the smoke from the 3R4F reference cigarettes. Most 
of these chemicals were either considered Generally recognized as Safe (GRAS) by the FDA (30 
chemicals) or used as ingredients to flavor the product (46 chemicals). Although the remaining 
ingredients were considered carcinogenic, Phillip Morris S.A, indicated that they didn’t pose a 
concern due to their low concentrations, which were below the permissible exposure limits 
(PELs) set by Occupation Safety and Health Administration (OSHA). The Center for Tobacco 
Products (CTP) did not agree with Phillip Morris S.A.’s interpretation of OSHA standards 
because they had no relationship in regard to how the THS 2.2 Menthol device would be used 
(FDA, 2019, p. 32). The PELs scope is limited to the workplace, which is not the only 
environment where the use of the Phillip Morris S.A. device would be used (FDA, 2019, p. 32).  
 By using the Organisation for Economic Co-operation and Development’s (OECD’s) 
Quantitative Structure-Activity Relationship, Phillip Morris S.A. was able to conduct further 
research into toxicity of these chemicals (FDA, 2019, p.32). The technique utilizes the molecular 
structures of the chemicals to estimate the potential dangers associated with their chemical 
properties. Ultimately, 19 of those original 80 chemicals, most of them being the flavoring 
ingredients, were found to be potentially genotoxic or carcinogenic. 
 Two in vitro tests used in the application were the Neutral Red Uptake (NRU) assay and 
Bacterial Reverse Mutation test. The aerosol and smoke of the products can be broken into two 
different groups: total particulate matter (TPM) and gas vapor phase (GVP). TPM consists of 
particles that can be trapped by a glass-fiber pad, while GVP refers to the particles that pass 
through the same pad. The Neutral Red Assay was used to detect viable cells after 24-hr 
exposure to culture medium containing the TPM or GPV fractions of the THS aerosol or the 
3R4F smoke. This experiment resulted in needing higher concentrations of the aerosol TPM and 
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GVP compared to the smoke of the 3R4F in order to reach an effective concentration that 
reduces the cell population by half (EC50), which indicates that the aerosol was less toxic. The 
Bacterial Reverse Mutation Test was used to find chemicals within the TPM fractions of the 
aerosol or the smoke causing bacteria to mutate (“Pre-Clinical Assessment Summary”, p. 3). The 
experiment found that unlike the reference cigarette, the fractions of the aerosol did not produce 
a mutagenic response within the bacteria.  
In vivo studies included a 3-month nose-only inhalation rat study and an 18-month 
carcinogenicity mouse study. In the first study, the rats were exposed to the smoke, aerosol, or 
filtered air, which was used as a control. There was a vast number of biological endpoints that 
were examined throughout the study. Overall, most of the endpoints were lower in the aerosol 
compared to the smoke. However, interestingly, the prevalence of cell hyperplasia, cell 
proliferation that leads to the enlargement of organs (commonly leading to cancer), were similar 
in the inhalations of aerosol and smoke. In the 18-month study, the same process was used but in 
mice. This was used to identify the risk of cancer. The conclusions from this study indicated that 
the was no increase risk to lung cancer for mice exposure to the THS 2.2 aerosol compared to the 
control group.  
 
Summary 
The research submitted in the PMTA provides evidence for three subject areas that are 
important in analyzing the risks of e-cigarettes: Smoking Topography, Assessment of Nicotine, 
and Aerosol Toxicity. In regard to smoking topography, the research included in the PMTA 
reveals that smoking behavior is different between the two products. Specifically, individuals 
using THS 2.2 Menthol device had a higher amount of puff, higher puff frequency, and higher 
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average flow rate. From the assessment of nicotine, the research focused on the 
pharmacodynamics of nicotine. Comparing the curves of the THS 2.2 Menthol device and the 
traditional cigarette, the assessment of nicotine showed that although they both contain nicotine, 
individuals using the THS 2.2 Menthol device were exposed to less nicotine. Finally, when 
assessing the toxicity of the aerosols from the THS 2.2 Menthol device, the results emphasize the 
toxicity of the aerosol. However, when the data is compared to that of the reference cigarette, 
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CHAPTER 5C: COMPARISON BETWEEN THE FINDINGS 
 From the PMTA, we can see that Phillip Morris S.A. included research from areas 
identified by the literature review as being important. Since these areas were covered, the next 
step to analyze the regulatory process is to compare the findings from the PMTA to the findings 
from the research gathered in the literature review. By comparing the finding, we can show 
whether the research within the PMTA was consistent with the ideas of the literature. 
 
Smoking Topography 
Although this PMTA evaluates multiple pieces of evidence submitted by Phillip Morris 
S.A. to validate the THS 2.2 Menthol device, the conclusions obtained are based on the 
comparisons between traditional cigarettes and e-cigarettes. These two devices provide a solution 
for the same need; however, the technology of their designs is vastly different. Literature can be 
used to provide examples supporting or opposing the claims founded from the data of the 
experiments used within the PMTA.  
From the literature review, research shows that there is dissimilarity in topography not 
only amongst the variation of e-cigarettes but also between traditional and electronic cigarettes.  
Like the research from the literature review, the findings of the PMTA also verify that smokers 
use traditional cigarettes and e-cigarettes differently. If these devices are used differently, should 
they still undergo the same evaluation process? There are many different behavioral aspects that 
play a role in analyzing the topography of smokers. Overall, the PMTA concluded that the 
smoking topography was different, however, Table 5 provides a closer look into specific 
variables within smoking topography. It will be used to illustrate whether the claims are 
supported by both the findings from the PMTA and the findings from the literature review.  
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Table 5: Variables that can be affected by smoking topography indicated by the findings within 
literature. 
Findings from Literature 
Review 
Agree with PTMA findings Implications 
for Consumer 
Safety/ Health 
E-cigarettes modify smoking 
behavior through having smaller 
and longer puffs. (Lee et al., 
2015) 
NO. The findings show that puff 
volume and puff duration were similar.  
HIGH 
Significant differences were 
indicated for puff volume due to 
the flavor of the e-cigarette. 
(Robinson et al., 2018) 
NO. There were no significant 
differences in puff volume. The PMTA 
focused on traditional and e-cigarettes, 
while the research focused only on e-
cigarettes. 
HIGH 
Nicotine levels change when puff 
durations are longer. (Farsalinos 
et al., 2017) 
Did not test. HIGH 
Lower nicotine e-liquids were 
associated with higher puffing 
topography (Dawkins et al., 
2016), which can increase 
exposure to Harmful and 
Potentially Harmful Constituents 
(Robinson & Hensel, 2019). 
Did not test. There was no variation 
between the amount of nicotine in the 
heatsticks used in the study. 
HIGH 
ENDS were significantly higher 
in total volume and inter-puff 
interval. (Norton et al. , 2014) 
YES. The was a difference between 
total volume between the two products. 
The THS 2.2 Menthol remained higher 
throughout the study. 
HIGH 
Significant differences were 
indicated for puff flow rate due to 
the flavor of the e-cigarette. 
(Robinson et al., 2018) 
YES. There was a difference between 
the puff flow rate but for the 
comparison of traditional and e-
cigarettes.  
MEDIUM 
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Topography changes can alter many of the processes that occur while smoking. For 
example, it can affect the chemicals and particles that are introduced to the user (Robinson and 
Hensel, 2019 & Farsalinos et al., 2017). Due to the hazard surrounding some of the chemicals, 
the health of the users can be altered due to how they are using the device. Although the 
parameters of the experiments within the PMTA do not focus on this relationship, topography 
can also be influenced by the strength of the nicotine that is used in the formula of e-liquids, or in 
this case the heatstick. Robinson and Hensel (2019) as well as Corocan (2016) found similar 
evidence that suggests that the concentration of nicotine can alter the behavior of the smoker.  
The support between literature and research completed within PMTA confirm that there are 
differences in the topography between smokers. There is, however, dissimilarity between the 
implications that this can have in regard to both the system and the user. 
 
Pharmacological Assessment of Nicotine 
Due to is addictive properties and reactions inside the body, the exposure of nicotine is 
really important, especially when considering the dangers of tobacco from a health perspective. 
Within the PMTA, the study focused on the pharmacokinetic factors associated with nicotine. 
Table 6 illustrates research that focuses on how nicotine is affected when comparing different 
tobacco products.  As previously mentioned, the literature shows that there is a difference 
between smoking topography between traditional cigarettes and e-cigarettes. However, due to 
the differences between findings, the review of literature was inconclusive in determining 
whether electronic cigarettes are capable of promoting smoking cessation. Within the PMTA, the 
research indicated there was higher nicotine exposure in traditional cigarettes compared to e-
cigarettes. Just because there is less exposure of nicotine compared to the traditional cigarettes, 
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does this mean the device safe? It indicates that there is less harm, but does less harm equate to 
more safety of the user?   
 
Table 6: Observation of the effects of smoking on nicotine within the literature. 
 
One thing that was not observed within the literature review was the comparison of e-
cigarettes to nicotine replacement therapy (NRT). Nicotine nasal spray (NNS) is used to help 
Findings from Literature 
Review 
Agree with PTMA findings Implications for 
Consumer Safety/ 
Health 
Levels of nicotine increased faster 
in the traditional cigarette 
compared to the cigalike and the 
tank model e-cigarettes (Rüther et 
al., 2018).  
NO. The THS 2.2 Menthol device 
reached its maximum nicotine 
concentration faster than the 
traditional cigarette   
HIGH 
The exposure to nicotine is 
impacted by the preference of the 
flavor. (Dempsey et al., 2017) 
NO. The PMTA found that they 
were comparable for both the fresh 
and menthol flavored heatsticks. 
HIGH 
Concentration of nicotine in the 
blood plasma increased 
significantly. (Dawkins & 
Corcoran, 2013) 
NO. Compared to the concentration 
of traditional cigarettes, the nicotine 
levels from the THS 2.2 Menthol did 
not increase significantly. 
HIGH 
The nicotine plasma 
concentrations were higher in 
traditional cigarettes. (Rüther et 
al., 2018) 
YES. The plasma concentrations 
were higher in traditional cigarettes. 
HIGH 
Urge to smoke decreased, but 
after the end of the smoking 
period is was not significant. ( 
Dawkins & Corcoran, 2013) 
NO. Craving reduction reduced, but 
it was still less than traditional 
cigarettes. 
HIGH 
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individuals quit smoking by lowering the symptoms associated with withdrawal. This area of the 
study indicated significant differences between the nicotine exposure of both the NNS and the e-
cigarette. Although the research within the PMTA shows the urge to smoke was less when using 
the NNS compared to the e-cigarette, the THS 2.2 Menthol system has the ability to expose users 
to both higher amounts of nicotine as well as a higher number of Harmful and potentially 
harmful constituents (HPHCs). This indicates that if smokers stop using traditional cigarettes, 
they would begin using a device that still can expose them to hazardous chemicals. One study 
within the PMTA focused on the likelihood of cigarette smokers in switching to electronic 
cigarettes (THS 2.2 Menthol). During a 6-week period, around thirty-four percent of individuals 
initially began using the e-cigarette, however, within that group only sixteen percent were solely 
using the THS 2.2 Menthol device by week 6, and sixteen percent of individual reverted to using 
traditional cigarettes prior to week 6. 
 Similar to the research within the PMTA, Hagedorn et al. (2013) found that the plasma 
nicotine levels are higher in traditional cigarettes, however, the findings between these two 
conflicts when looking at the time it takes to reach the maximum nicotine plasma concentration. 
The research in the PMTA shows a shorter time for individuals using the THS 2.2 Menthol, 
while the Hagedorn et al. (2013) indicates the traditional cigarettes were shorter. Differences in 
time it takes to reach the maxima could not only have implications in understanding more about 
user satisfaction as well as why smokers continue to smoke. 
 
Aerosol Toxicity 
Although there is less exposure to nicotine in electronic cigarettes, it does not discount 
the other harmful chemicals that are within both types of cigarettes. Within the PMTA, there is 
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an abundance of studies that focus on the toxicity of aerosols. Before these compounds and 
chemicals can be tested for toxicity, they first have to be identified. Using different methods to 
capture particulates from the TPM or the GVP can lead to different results (Eddingsaas et al., 
2018). Within their study, Eddingsaas et al. (2018) found that particles differ depending on the 
substance that you are testing, either the aerosol or the e-liquid. They also found differ by the 
method you are collecting them, for example, filter pads or methanol impingers have different 
efficiencies during collection. The variations between methods and results confirm the need for a 
standardized method of identifying chemicals in e-cigarette. The individuals from the Center for 
Tobacco Products also suggested their uncertainty about how Phillip Morris S.A.’s collection 
method could possibly impact the study.  
From the research within Table 7, there are a number of considerations that need to be 
made when evaluating electronic cigarettes. During their research, Olmedo et al., (2018) found 
that metals can be transferred through the smoking process using e-cigarettes. Although there 
was data in the PMTA examining the engineering aspect of the THS 2.2 system, there were no 
tests investigating the potential cross-contamination between the metal of the device and product. 
Most of the comparisons within the PMTA focused on comparing traditional cigarettes to the 
electronic cigarettes, however, due to the differences in technology there are more areas that 
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Findings from Literature Agree with PTMA findings Implications for 
Consumer Safety/ Health 
There are a variety of chemical 
reactions that occur through the 
process of using an e-cigarette. 
(Strongin, 2019) 
YES. The PMTA tested the 
ingredients within the heatstick 
aerosol.  
HIGH 
E-cigarettes have a higher number of 
radon decay products, which led to an 
increase in the particle number 
concentration. (Vargas Trassiera et 
al., 2014) 
Did not test. The PMTA only 
tests the toxicity of the 
ingredients found in the aerosol. 
LOW 
The use E-cigarettes enable metals to 
be transferred, exposing the users to 
toxic materials. Found that metal 
concentrations were higher in the 
aerosol than the tank. (Olmedo et al., 
2018) 
Did not test. The PMTA does 
not disclose the particles within 
the TPM just the comparison 
between the two products. 
HIGH 
Some methods provide different 
levels of accuracy in capturing the 
compounds with the aerosol and the 
e-liquids. (Eddingsaas et al., 2018) 
Did not test. The only thing 
altered were the smoking 
regimens of the smoking 
machines. PMTA did not 
disclose what they used to 
capture the TPM or the aerosols. 
HIGH 
Cell-specific responses were 
dependent on the chemical introduced 
to the cells. Some responses were 
more potent than others. (Gerloff et 
al., 2017) 
Did not test. The in vitro studies 
indicated toxicity but did not 
show how function was altered.  
HIGH 
 Lara 40 
CHAPTER 5D: QUALITY OF DATA 
The studies previously mentioned allow the Center for Tobacco Products to conclude that 
these devices are safe for the public. Although most of the evidence support these claims, there 
are a number of concerns within the studies that could potentially impact the decision to approve 
the device. 
This smoking topography study was done in order to determine differences; thus, these 
differences could illustrate how smokers really interact with the THS 2.2 Menthol device which 
are different from traditional cigarettes. Researchers claimed that these disparities were caused 
by the “process of adaptation” for participants using the THS 2.2 Menthol. These devices are 
different, so the method or technique of smoking would be modified. However, in order to 
counteract these adjustment effects regarding the device properly in the study, researchers could 
have either conducted a longer study, provided a more extensive tutorial about the THS 2.2 
menthol devices, or given a longer period in the controlled environment to assess whether 
participants were using the new device properly. 
The design of the pharmacology study of nicotine could have been altered to create a 
more compelling argument. The behavioral data collected from the smoking topography study 
indicates that there is a difference between the smoking behavior when using the different 
tobacco products. As a result, smoking preference could influence the amount of nicotine 
introduced in the system of the smokers due to their smoking behavior. Also, the MCEQ in the 
behavioral study shows that over the 90 days smokers start altering their opinions of the device. 
This introduces whether 5 days is enough for smokers to develop a consist smoking behavior that 
reflects how individuals using the new THS 2.2 Menthol device would use the product.  
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Overall, the CTP found that it was difficult to assess the long-term exposure using the 
data provided from the in vitro and in vivo studies. For example, most data within the in vitro 
studies confirmed that the THS 2.2 Menthol device needed higher concentrations to create the 
similar toxic effects as the 3R4F. However, the CTP noted that there is no validation behind the 
method of generating the aerosols of the heatsticks. For the in vitro studies, the CTP also 
indicated concerns about accepting whether the studies provide enough evidence to accurately 
predict the carcinogenic potential of aerosol exposure. 
 
Overall 
 Although most of the categories associated with high health implications were covered 
in the PMTA, majority of its findings were not consistent with the research from the literature 
review. This section, however, emphasizes the findings that were not covered in the PMTA, 
which are also are illustrated in Table 8. Although some of the experiments in Table 8 are not 
applicable with research within the PMTA, they are still included because of their implications 
regarding consumer safety. For example, Corocan (2016) as well as Robinson & Hensel (2019) 
showed that the strength of nicotine impacts smoking behavior. Although the THS 2.2 Menthol 
doesn’t use e-liquids, an experiment still could have looked at the how the strength of the 
Heatsticks impacts user behavior. One area that was overlooked within the PMTA was the 
studies that show the interaction of all the device components. The research conducted by 
Olmedo et al. (2018) reveal that users can be exposed to metal components that are inside the 
device. This has a huge impact in consumer safety due to the design of e-cigarettes, which use 
different metals. Due to their significance, these areas should be incorporated into the PMTA 
process so that the entirety of the device is accurately analyzed. 
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Table 8: Findings from the literature review that were not covered within the PMTA 
 
Findings from Literature Review Agree with PTMA findings Implications for 
Consumer Safety/ 
Health 
Nicotine levels change when puff durations 
are longer. (Farsalinos et al., 2017) 
Did not test. HIGH 
Lower nicotine e-liquids were associated 
with higher puffing topography (Dawkins et 
al., 2016), which can increase exposure to 
Harmful and Potentially Harmful 
Constituents (Robinson & Hensel, 2019). 
 Did not test. There was no 
variation between the amount 
of nicotine in the heatsticks 
used in the study. 
HIGH 
E-cigarettes have a higher number of radon 
decay products, which led to an increase in 
the particle number concentration. (Vargas 
Trassierra et al., 2014) 
Did not test. The PMTA only 
tests the toxicity of the 
ingredients found in the aerosol. 
LOW 
The use E-cigarettes enable metals to be 
transferred, exposing the users to toxic 
materials. Found that metal concentrations 
were higher in the aerosol than the tank. 
(Olmedo et al., 2018) 
Did not test. The PMTA does 
not disclose the particles within 
the TPM just the comparison 
between the two products. 
HIGH 
Some methods provide different levels of 
accuracy in capturing the compounds with 
the aerosol and the e-liquids. (Eddingsaas et 
al., 2018) 
Did not test. The only thing 
altered were the smoking 
regimens of the smoking 
machines. PMTA did not 
disclose what they used to 
capture the TPM or the 
aerosols. 
HIGH 
Cell-specific responses were dependent on 
the chemical introduced to the cells. Some 
responses were more potent than others. 
(Gerloff et al., 2017) 
Did not test. The in vitro studies 
indicated toxicity but did not 
show how function was altered.  
HIGH 
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CHAPTER 6: DISCUSSION & CONCLUSION 
Within this chapter, I will discuss the implications of the PMTA analysis, summarize the 
limitations of research, and provide recommendations for the current evaluation process of e-
cigarettes. 
 
CHAPTER 6A: IMPLICATIONS OF THE PMTA 
 The main comparison being made throughout the entirety of the PMTA is between 
traditional cigarettes and e-cigarettes. All of the research conducted include the use of traditional 
cigarettes to show the differences in the levels of harm between the two products. Throughout 
most of the PMTA, the evidence provided depicts the image that electronic cigarettes are less 
harmful than traditional cigarettes; however, less harmful does not equate to harmless. These 
devices are “less harmful” compared to traditional cigarettes, which have been known to have 
detrimental effects. This means that the device is still harmful. If the foundation of this analysis 
was based solely on e-cigarettes, rather than a comparison, would the decision of the CTP to 
approve this device be the same?  
The first research question of this thesis surrounds whether the evidence provided by 
companies was substantial. This question was used to examine not only the information that 
companies provided, but also the strength of the evidence used to justify the safety of the 
electronic cigarette device. The PMTA completed by Phillip Morris incorporated different areas 
of research, however under closer observation, the work done does not provide strong enough 
arguments to be considered substantial.  
Some of the experiments that were selected to build arguments for the safety of the THS 
2.2 Menthol device, in particular, were either not verified or did not show conclusive results. As 
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previously shown, the Center for Tobacco Products had concerns regarding the in vitro tests, 
which were used to show the carcinogenic potential of the aerosol. They also were unsure 
whether using the particulate matter or the gas vapor phase impacted the results of the 
experiments that were being done. These questions regarding the quality of the experiments 
ultimately reduce the efficiency of the regulation process. If companies are able to submit 
evidence that doesn’t solidify a strong argument of safety, then the decision by the Center for 
Tobacco Products to mark these devices as safe doesn’t rely solely on the science.  
One main focus of this regulation is to accurately assess the safety of these devices. If 
there are holes in the argument, like the inconclusiveness of results, then how can the FDA 
support the idea that these devices are safe. Within the process of regulating these devices, the 
FDA can request more information from the companies. However, it seemed as though these 
instances of concern or evidence of ambiguity did not warrant the FDA to pursue this route. 
From the PMTA, we see Phillip Morris includes multiple studies to justify the safety of 
the THS 2.2 Menthol device. Although there is an abundance of evidence provided, there are still 
questions surrounding the quality of the experiments they chose to include. The FDA has the 
final decision in approving these devices, but they have to determine whether the evidence 
provided is satisfactory in showing safety. Despite approving these devices, the FDA was not 
able to accurately assess the THS 2.2 Menthol device due to the limitations of the research that 
was provided.  
The second research question addresses whether the regulation process is effective for 
analyzing e-cigarette devices. Despite the inclusion of important research areas in the PMTA, 
more research needs to be done in order to effectively analyze e-cigarette devices. The emphasis 
of traditional cigarettes within the PMTA eliminated the need for research that placed attention 
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on simply e-cigarettes. For example, the in vitro studies focused only on the toxicity of the 
aerosols in relation to genetics, however, there was no research that indicated whether the use of 
this device generates functional changes in the cells. The lungs are an important part of 
respiratory system, particularly for its blood-air interface, which regulate gas exchange within 
the body. The barrier associated with the cells of the lungs have the ability to filter particles, 
restricting them from entering the bloodstream. Since the route of transmission affects the 
respiratory system, research that shows how the aerosols affect cellular structures should be 
important in the assessment of the e-cigarettes. 
Also, the representation of potential users was limited within all of the clinical studies. 
Phillip Morris S.A. claimed that the THS 2.2 Menthol device was only aimed at current and 
former smokers, but the studies focused solely on current smokers. Groups of individuals, like 
former smokers, non-smokers and youth, were not included. Phillip Morris S.A. used data from a 
likelihood of use study to verify the potential types of users that would interact with their 
product. From the study, Phillip Morris S.A. concluded that these groups were not going to be 
using their products. However, McKenley et al. (2018) found that Phillip Morris’s data was 
unsuccessful in confirming that youth, specifically, would neither find their products alluring nor 
start using them [20]. From the current increase use of e-cigarettes by the youth, the results from 
Phillip Morris seem likelihood of use study seem unlikely.  
Within their application, Phillip Morris S.A indicated that the FDA did not expect youth 
representation within the studies. However, like most of their research in the PMTA, which 
focused on the comparison between cigarette products, Phillip Morris S.A. could have included 
information about the youth interactions with any of their other products for a comparison but 
did not (p.76). By limiting the research to individuals who are current smokers, we are unaware 
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of the effects that could happen for individuals who do not smoke but would consider using e-
cigarettes. 
Finally, many of the conclusions from the studies included within the PMTA were not 
supported by the research from the literature, which had high implication for the health of the 
consumer. Some elements were not even examined within the PMTA. There are a multitude of 
differences between traditional cigarettes and e-cigarettes, especially when considering 
technology. The system of Phillip Morris is more complex than a traditional cigarette, yet no 
research looked at whether the heating elements of the system interacted with the user. Since 
they were not addressed, it is difficult to say that this process is effective because not all of the 
health implications are considered when analyzing e-cigarettes.  
 The effectiveness of the regulation process for e-cigarettes is limited by the 
process that is currently in place to evaluate its predecessor, the traditional cigarette. To be 
effective, the process for regulating e-cigarettes cannot rely solely on the research that is required 
for traditional cigarettes. The research needs to include information that focuses on the 
technological differences that makes these devices, e-cigarettes, more complex than traditional 
cigarettes. The regulation process was effective due the inclusion of important research areas 
required in analyzing these devices, however, in order to make an accurate evaluation of these e-
cigarette devices, more focus needs to be placed on the e-cigarettes rather than the comparison 
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CHAPTER 6C: LIMITATIONS OF RESEARCH  
The biggest limitation of the research conducted in this thesis is the access to PMTAs. 
There was only one application for e-cigarettes available on the FDA website. In order to 
effectively assess the evaluation process of these devices, more applications should be used to 
develop a more comprehensive understanding of the research being provided by companies. 
More applications would affirm whether companies are relying specifically on traditional 
cigarettes to develop conclusions about their devices. By only using the Phillip Morris’ 
application, I am limited to a single process for one type of e-cigarette device. 
While the heatsticks of Phillip Morris’ device do contain propylene glycol, a humectant 
found in e-liquids, many of the e-cigarettes marketed have a variety of flavors and formulas that 
contain a larger number of liquid components, which would certainly impact the research that is 
required. When heated, the e-liquid undergoes a phase change, going from liquid to vapor. Thus, 
companies would need to determine whether the vapors return to liquid when exposed to the 
temperature of the body. They would also have to show how these particles interact with the 
body in both the vapor and liquid form. Within the Phillip Morris application, there were three 
heatstick: Marlboro, smooth menthol and fresh menthol. The research for each heatstick was 
done separately, however, to make a direct comparison of the two the experiments should have 
been conducted together. The conclusion was that the flavor had no impact on the study, 
however, that is contradictory to a recurring idea within the literature. 
 The research in this thesis was further limited by the redactions within the PMTA 
application. Sections containing information about the engineering of device were marked, 
limiting my ability to examine evidence concerning the device. This could potentially impact my 
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analysis, because it restricts the information that can be used to justify the safety of the THS 2.2 
Menthol device. 
  
CHAPTER 5C: RECOMMENDATIONS 
Overall, the process for the evaluation of e-cigarettes is very broad. The companies are 
responsible for providing information they deem relevant. Thus, there is no standard for what 
research is required. Within the PMTA, there was hesitancy by the Center for Tobacco Products 
to accept some of the experimental research that was included. There was also uncertainty 
regarding whether the methods for sample collection within the experiments would impact the 
results of studies. Although companies are responsible for providing research, the CTP should 
develop acceptable tests or at least guidelines for what needs to be shown, especially in the areas 
of research. 
 One part of the process that should be altered is the labeling and the determination of 
potential users. The data from Phillip Morris indicated that youth interactions with this device 
were low. However, an overwhelming number of youths have become e-cigarette users. The 
FDA should require marketing research where either companies or the FDA host a meeting with 
a variety of individuals to see the prevalent opinions being made about the device for all groups, 
including children. This would help discover potential users and help companies learn what 
characteristics of their products need to be altered to lower their appeal to youth. In addition to 
the likelihood of use study, Phillip Morris relied on areas where their device was already 
marketed to help affirm the notion that the likelihood of youth use would be lower. Although the 
evidence could be persuading, these places, like Japan, have different cultures than the United 
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States; thus, they cannot be used to accurately model or predict what would happen in the United 
States. 
 Another recommendation would be to increase the availability and accessibility of 
information for PMTAs. Transparency not only allows the government to be accountable, but 
also allows the public to understand processes that are in place to protect them. Lack of 
transparency can impact the relationship between the public and government, creating mistrust 
and restlessness towards the government. The inability to gather information about PMTAs 
impacts the analysis of this thesis. It limits not only what I was able to find, but also what I was 
conclude. The inability to gather information also impacts the information being reported on the 
FDA website. When looking into the different pathways of process, there were tables responsible 
for tracking the frequency of pathways used by companies, however, these tables were unable to 
depict the breakdown of the type of product. This emphasizes the need for more information 
because how would individuals know whether type of product a company makes impacts the 
pathway it would use. This would be helpful in showing whether e-cigarettes or traditional 
cigarette companies favor one pathway over the others.  
 In order to increase transparency, there should be more information available for 
monitoring the regulation process. One way to accomplish this would be to create a database that 
includes e-cigarette products involved with the regulation process. This would be helpful in 
illustrating whether companies are approved and whether they are in the process of approval 
allowing individuals to know more about the products they are using.  
 In addition to the accessibility of information, the process of enforcing the regulation for 
e-cigarettes needs to be improved. A multitude of e-cigarette products did not undergo the 
regulation process, yet they were still being sold on the market. By allowing these products to be 
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marketed without approval, the FDA allowed companies to bypass the regulation process and to 
introduce potentially harmful products onto the market. This means that e-cigarette companies 
were not held accountable for the products that they were producing for consumers.  
In July of 2019, the courts mandated the FDA to issue a deadline for marketed e-cigarette 
products that would require companies to submit a PMTA by May 12, 2020. Due to the COVID-
19 pandemic, this deadline for the PMTAs was further postponed until September. This mandate, 
however, does not provide an optimal solution because companies are still able to market their 
device up to one year while their applications are under review by the FDA. Ultimately, this 
allows the public to still interact with devices that have not been deemed safe for consumer use. 
In order to decrease the threat of these devices, e-cigarettes that have not received a marketing 
order should be taken off the market, especially if they were placed on the market after the FDA 
received the power to regulate electronic cigarettes. If companies are allowed to continue 
marketing their devices, the system created to regulate these devices would be contradicted. 
These devices were not supposed to be marketed until receiving a market order from the FDA, 
which did not occur. Thus, allowing e-cigarette devices to stay on the market decreases the 
enforcement of the regulation process. 
Another area that should be focused on is the flavoring of e-liquids, which is the greatest 
obstacle against deterring youth from e-cigarettes. There are a multitude of flavors, like candy, 
that entice children to use these products. Flavors have been associated with the perception of 
less risk; thus, more needs to be done in order to provide a solution. Prior to the federal flavoring 
ban, states and local governments were enacting flavor bans to protect their constituents against 
the products. These actions helped initiate the federal ban on that went into effect in February 
2020. This is probably the most effective way to prevent children from using e-cigarettes, 
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however, there are children who have already become consistent users. In order to show the 
children who already have been affected the risks, more research needs to be done to determine 
the mechanisms that make these devices dangerous so that the public can be aware of the all the 
risks associated with using e-cigarettes. Also, the information can be used in the current 
campaigns that are used to dissuade youth from using these products. 
  Although these devices are not used for medical purposes, the design of e-cigarettes are 
similar to the medical devices that deliver substances to individuals. Due to the complexities of 
its design, e-cigarettes seem more comparable to medical devices than traditional cigarettes. E-
cigarettes are regulated the same as cigarettes because they include nicotine, however, most of 
the tobacco products under this regulation have simplistic designs. The evaluation of these 
process does not account for the intricacies associated with technology within the systems of e-
cigarettes. The research has to account for more than what is provided for traditional cigarette, 
which is the limitation of the research included in the PMTA. In order to improve the process, 
more research needs to be done to understand interactions of the devices within all levels of the 
system. 
 The improvement of the PMTA surrounds increasing the validity and quality of research. 
The broadness of the current process gives too much control to the companies, which allow them 
to pick and choose what evidence they provide. By requiring guidelines around research, the 
FDA can strengthen its expertise while holding companies more accountable for what they 
include in their PMTA. Another way to improve the process is to implement some of 
characteristics of the process for the regulation of Class II and Class III medical devices, which 
undergo a high level of scrutiny by the Center for Devices and Radiological Health. This can 
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allow insight from technical expertise, which focuses on the entire system rather focusing on the 
delivery of the nicotine. 
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Appendix 1: Denial for the request of additional PMTAs  





 Lara 63 
 
 
